| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, will host a virtual investor event reviewing preliminary clinical data from its Phase 1 dose-escalation study of VIP236 and provide an update on pipeline progress on Monday, April 8, 2024, at 2 PM PT. This will follow the poster presentation of the VIP236 clinical data at the AACR Annual Meeting 2024.
The virtual investor event will include presentations by Ahmed Hamdy, MD, CEO of Vincerx Pharma, along with key opinion leaders, Uma Borate, MD, MBBS, Clinical Associate Professor in the Division of Hematology at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and Vivek Subbiah, MD, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute.
To register and view the live webcast, please visit: https://edge.media-server.com/mmc/p/xhv7kxf7/. An archived replay of the webcast will be available on the Vincerx Investor Page website following the conclusion of the live event.
Posted In: VINC
